Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | FKBP1A | P62942 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.36 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1779547 | 1.00 | L3MBTL1 (0.38) | L3MBTL1KMT2AATMFKBP1APOLB | |
| SCHEMBL5643023 | 0.95 | POLB (0.42) | L3MBTL1POLBRAB9AHRH3 | |
| SCHEMBL28153696 | 0.95 | POLB (0.42) | L3MBTL1POLBRAB9AHRH3 | |
| SCHEMBL2463944 | 0.88 | BRD4 (0.37) | L3MBTL1KMT2APOLBALDH1A1KDM4E | |
| SCHEMBL11996941 | 0.88 | BRD4 (0.37) | L3MBTL1KMT2APOLBALDH1A1KDM4E | |
| SCHEMBL12606506 | 0.87 | CHRM2 (0.41) | L3MBTL1ATMFKBP1APOLB | |
| SCHEMBL3032831 | 0.84 | L3MBTL1 (0.39) | L3MBTL1KMT2AATMFKBP1APOLB | |
| SCHEMBL25162000 | 0.83 | ATM (0.43) | L3MBTL1KMT2AATMFKBP1APOLB | |
| SCHEMBL14140345 | 0.83 | ALDH1A1 (0.40) | KMT2AALDH1A1NPC1HPGDRAB9A | |
| SCHEMBL30129954 | 0.83 | HSD17B10 (0.37) | L3MBTL1FKBP1APOLBNPC1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107540599-B | Aminoindane compounds and their use to treat pain | 阿萨纳生物科技有限责任公司 | 2021-06-04 | — | — | CN | disclosed |
| CN-107540599-A | Aminoidan compound and its purposes for treating pain | 阿萨纳生物科技有限责任公司 | 2018-01-05 | — | — | CN | disclosed |
| US-20100210667-A1 | IMIDAZO [1, 2-C] PYRIMIDIN-2-YLMETHYLPIPERIDINES AS OREXIN RECEPTOR ANTAGONISTS | ALVARO GIUSEPPE | 2010-08-19 | — | — | US | disclosed |
| WO-2010072722-A1 | PIPERIDINE DERIVATIVES USEFUL AS OREXIN ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2010-07-01 | — | — | WO | disclosed |
| US-20100160344-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-06-24 | — | — | US | disclosed |
| WO-2010060470-A1 | PIPERIDINE DERIVATIVES USEFUL AS OREXIN RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2010-06-03 | — | — | WO | disclosed |
| WO-2010060471-A1 | PIPERIDINE DERIVATIVES USEFUL AS OREXIN RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2010-06-03 | — | — | WO | disclosed |
| WO-2010060472-A1 | IMIDAZOPYRIDAZINE DERIVATIVES ACTING AS OREXIN ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2010-06-03 | — | — | WO | disclosed |
| EP-2176258-A1 | PIPERIDINE DERIVATIVES USEFUL AS OREXIN RECEPTOR ANTAGONISTS | Glaxo Group Limited (GB) | 2010-04-21 | — | — | EP | disclosed |
| EP-2176265-A1 | IMIDAZO [1, 2-C]PYRIMIDIN-2-YLMETHYLPIPERIDINES AS OREXIN RECEPTOR ANTAGONISTS | Glaxo Group Limited (GB) | 2010-04-21 | — | — | EP | disclosed |
| US-20090022670-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2009-01-22 | — | — | US | disclosed |
| WO-2009003997-A1 | IMIDAZO [1, 2-C] PYRIMIDIN-2-YLMETHYLPIPERIDINES AS OREXIN RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2009-01-08 | — | — | WO | disclosed |
| WO-2009003993-A1 | PIPERIDINE DERIVATIVES USEFUL AS OREXIN RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2009-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090022670-A1 | NOVEL COMPOUNDS | UGT1A1, UGT2B7, ABCB1 | L3MBTL1 4844/4885KMT2A 3634/4885ATM 4432/4885 |
| US-20100160344-A1 | NOVEL COMPOUNDS | BRD4, HDAC6, ENTPD5 | L3MBTL1 4441/4885KMT2A 3341/4885ATM 4547/4885 |
| US-20100210667-A1 | IMIDAZO [1, 2-C] PYRIMIDIN-2-YLMETHYLPIPERIDINES AS OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPY2R | L3MBTL1 4464/4885KMT2A 640/4885ATM 4777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.